Neuropathic Pain Clinical Trial
— HALOOfficial title:
The Pain Suppressive Effect of Low Frequency Spinal Cord Stimulation Versus High Frequency Spinal Cord Stimulation
Verified date | November 2020 |
Source | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Electrical stimulation of the spinal cord (Spinal Cord Stimulation or SCS) for pain relief has been used for decades. It is used most commonly in patients with chronic neuropathic leg pain, after spinal surgery. Conventional neurostimulation is applied in frequencies of 30 to 60 Hertz (Hz) and perceptible paraesthesias are felt. Stimulation using higher frequencies with sub perception paraesthesias has recently challenged the conventional form of neurostimulation.The high frequency stimulation appears to show better pain relief for both back and limb pain in comparison to low frequency SCS, and may also to be effective in some subjects who did not respond to low frequency SCS.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 30, 2018 |
Est. primary completion date | November 17, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Male/female, 18 years to 70 years - Chronic, persistent, refractory, unilateral neuropathic limb pain, as a result of spinal surgery - Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and minimally interventional pain procedures for chronic pain - Pain radiating in the leg, following segments L4 and/or L5 and/or S1 for at least 6 months - Minimum baseline pain intensity as assessed by VAS of = 50mm on 100mm scale in the primary pain area - Subject is able and willing to provide informed consent - Subject is able and willing to comply with the protocol and follow-up schedule - Subject has been included for implantation according to standard criteria from the Dutch Neuromodulation Society Exclusion Criteria: - Back pain component of more than 20% or VAS > 40mm on 100mm scale - Bilateral limb pain - Subjects with a previous SCS implantation. - Changes in pain medication in the 2 months preceding the trial period; - Expected inability of subjects to correctly operate the neurostimulation system - Presence of any other clinically significant or disabling chronic pain condition -eg. hip arthrosis, rheumatoid arthritis, fibromyalgia, etc. - History of coagulation disorders, lupus erythematosus, diabetes mellitus, or morbus Bechterew - Symptoms or proof of any malignant disease - Current use of medicines affecting coagulation which cannot be temporarily stopped - Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact the perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by the investigator - Life expectancy of less than 1 year - Existing or planned pregnancy in the trial period - BMI >20 and <35 - a minimum and maximum BMI limit are imposed due to the technical difficulties and risk of complications in underweight or morbidly obese subjects. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Medisch Centrum Alkmaar | Alkmaar | North Holland |
Netherlands | Academic Medical Center | Amsterdam | North Holland |
Netherlands | Alrijne Hospital | Leiderdorp | South Holland |
Netherlands | Rijnstate Hospital | Velp | Gelderland |
Netherlands | Diakonessenhuis | Zeist | Utrecht |
Lead Sponsor | Collaborator |
---|---|
Jennifer Breel | Alrijne Hospital, Diakonessenhuis, Utrecht, Noordwest Ziekenhuisgroep, Rijnstate Hospital |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Visual Analog Pain Scores (VAS) | 0mm to 10mm line scale, where higher score is better, measured 4 times a day at 09:00, 15:00, 21:00 and a nightscore measured first thing in the morning | 24 days | |
Secondary | Visual Analog Pain scores (VAS) | 0mm to 10mm line scale, where higher score is better, measured 4 times a day at 09:00, 15:00, 21:00 and a nightscore measured first thing in the morning | 12 months | |
Secondary | EuroQoL 5Dimensions-3Levels | Quality of LIfe, 5 questions measured on 3 levels (mild =1, moderate=2, severe=3). Higher score is worse. Each domain calculated according to a national index. | 1 month, 12 months | |
Secondary | Short Form-36 | Quality of Life, 36 questions with differing formats, 8 domains, higher score is better | 1 month, 12 months | |
Secondary | Sleep questionnaire | Quality of sleep before and after stimulation, Several Likert-type items 0-5 and 0-7, higher score is better | 1 month, 12 months | |
Secondary | GPES | Subject satisfaction,1 Likert-type item 0-7, higher score is better | 1 month, 12 months | |
Secondary | Employment status | Change in employment status, open question whether or not employment status has changed and how many hours per week persons were/not working | 12 months | |
Secondary | (Serious) Adverse Events | Number of patients with device related events such as lead dislocation, infections, pocket pain, increase in pain whilst using one paticular frequency etc. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 |